肠道菌群及其代谢产物对冠心病影响的研究进展

doi:10.3969/j.issn.1003-9198.2021.09.019

[1] TANG W H W, KITAI T, HAZEN S L. Gut microbiota in cardiovascular health and disease[J]. Circ Res, 2017, 120(7):1183-1196.
[2] JANDHYALA S M, TALUKDAR R, SUBRAMANYAM C, et al. Role of the normal gut microbiota[J]. World J Gastroenterol, 2015, 21(29):8787-8803.
[3] SOMMER F, ANDERSON J M, BHARTI R, et al. The resilience of the intestinal microbiota influences health and disease[J]. Nat Rev Microbiol, 2017, 15(10):630-638.
[4] EMOTO T, YAMASHITA T, KOBAYASHI T, et al. Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease[J]. Heart Vessels, 2017, 32(1):39-46.
[5] CHAN Y K, BRAR M S, KIRJAVAINEN P V, et al. High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE mice[J]. BMC Microbiol, 2016, 16(1):264.
[6] MALIK M, SUBOC T M, TYAGI S, et al. Lactobacillus plantarum 299v supplementation improves vascular endothelial function and reduces inflammatory biomarkers in men with stable coronary artery disease[J]. Circ Res, 2018, 123(9):1091-1102.
[7] BROWN J M, HAZEN S L. Microbial modulation of cardiovascular disease[J]. Nat Rev Microbiol, 2018, 16(3):171-181.
[8] WATANABE M, HOUTEN S M, MATAKI C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation[J]. Nature, 2006, 439(7075):484-489.
[9] DUBOC H, AELION H, RAINTEAU D, et al. Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor[J]. Hepatology, 2012, 56(6):2426.
[10] 张琪, 宋晓鹏, 任茂佳, 等. 氧化三甲胺与心血管疾病的研究新进展[J]. 心血管病学进展, 2020, 41(1):81-84.
[11] CHEN M L, ZHU X H, RAN L, et al. Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway[J]. J Am Heart Assoc, 2017, 6(9):e006347.
[12] SENTHONG V, WANG Z, LI X S, et al. Intestinal microbiota-generated metabolite Trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort[J]. J Am Heart Assoc, 2016, 5(6):e002816.
[13] SCHIATTARELLA G G, SANNINO A, TOSCANO E, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis[J]. Eur Heart J, 2017, 38(39):2948-2956.
[14] NEMET I, SAHA P P, GUPTA N, et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors[J]. Cell, 2020, 180(5):862-877.
[15] TAN Y, ZHANG H, GUO D, et al. Adipophilin involved in lipopolysaccharide-induced inflammation in RAW264.7 cell via extracellular signal-regulated kinase 1/2-peroxisome proliferator-activated receptor gamma pathway[J]. DNA Cell Biol, 2017, 36(12):1159-1161.
[16] CHISTIAKOV D A, BOBRYSHEV Y V, KOZAROV E, et al. Role of gut microbiota in the modulation of atherosclerosis-associated immune response[J]. Front Microbiol, 2015, 6:671.
[17] MARQUES F Z, NELSON E, CHU P Y, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice[J]. Circulation, 2017, 135(10):964-977.
[18] ESTHER L G, FERNANDO R A, LI T Y, et al. The Mediterranean-style dietary pattern and mortality among men and women with cardiovascular disease[J]. Am J Clin Nutr, 2014, 99(1):172-180.
[19] MANGELS D R, MOHLER E R. Catechins as potential mediators of cardiovascular health[J]. Arterioscler Thromb Vasc Biol, 2017, 37(1):757-763.
[20] LI D, WANG P, LUO Y, et al. Health benefits of anthocyanins and molecular mechanisms:update from recent decade[J]. Crit Rev Food Sci Nutr, 2017, 57(8):1729-1741.
[21] CHEN L, LIU W, LI Y, et al. Lactobacillus acidophilus ATCC 4356 attenuates the atherosclerotic progression through modulation of oxidative stress and inflammatory process[J]. Int Immunopharmacol, 2013, 17(1):108-115.
[22] PARCHURE N, ZOURIDAKIS E G, KASKI J C. Effect of azithromycin treatment onendothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection[J]. Circulation, 2002, 105(11):1298-1303.
[23] 罗晓雅, 杨志宏. 肠道菌群与心血管疾病相关性的研究进展[J]. 中国药理学通报, 2018, 34(8):1037-1041.
[24] WANG Z, ROBERTS A B, BUFFA J A, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis[J]. Cell, 2015, 163(7):1585-1595.
[25] BRUGÈRE J F, BORREL G, GACI N, et al. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease[J]. Gut Microbes, 2014, 5(1):5-10.
[26] GREGORY J C, BUFFA J A, ORG E, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation[J]. J Biol Chem, 2015, 290(9):5647-5660.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui, LIN Song. Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure [J]. Practical Geriatrics, 2024, 38(10): 1025-1029.
[2]	XU Shouyong, YUAN Yong. Study on feasibility of dual-low-dose CT coronary angiography in elderly patients [J]. Practical Geriatrics, 2024, 38(10): 1054-1058.
[3]	ZHA Zhimin, LIU Huan, WANG Xiangming, LI Qiushuang, GUO Yan. Effect of cardiac valve calcification on prognosis of elderly patients with coronary heart disease [J]. Practical Geriatrics, 2024, 38(3): 245-250.
[4]	. [J]. Practical Geriatrics, 2024, 38(3): 308-311.
[5]	ZHANG Ying, XIE Ling, YE Jiaqi, QIANG Wenhui, YAN Xiaoyun, JIANG Ying, ZHANG Qing. Correlation between laminin and major adverse cardiovascular events in elderly patients with acute myocardial infarction [J]. Practical Geriatrics, 2024, 38(2): 149-151.
[6]	YANG Xue, NING Chun, ZHAO Juan, HAO Jing-bo, YANG Rong-li. Diagnostic value of growth differentiation factor 15 and cytokines in elderly patients with coronary heart disease complicated with frailty [J]. Practical Geriatrics, 2023, 37(10): 1009-1013.
[7]	ZHENG Ya-guo, XU Tian, ZUO Guang-feng, CHEN Liang, LIN Song. Effect of drug-coated balloons in patients with Medina 0,0,1 coronary bifurcation lesion [J]. Practical Geriatrics, 2023, 37(6): 599-602.
[8]	SONG Chun-mei, YIN Ya-juan, LIU Yong-sheng, GUO Qi-feng, CHEN Jie, WEI Mei. Predictive value of anxiety on adverse cardiovascular events in elderly patients after percutaneous coronary intervention [J]. Practical Geriatrics, 2023, 37(4): 352-355.
[9]	. [J]. Practical Geriatrics, 2023, 37(4): 395-397.
[10]	JIANG Lei, JIA Zhi-qiang, YU Jian, LI Xiao-qing, ZHANG Dong-mei, HUANG Jing-jing. Effects of intensive rosuvastatin treatment on the inflamm-aging related indexes and clinical efficacy in elderly patients with acute coronary syndrome receiving percutaneacs coronary intervention [J]. Practical Geriatrics, 2023, 37(3): 265-269.
[11]	. [J]. Practical Geriatrics, 2023, 37(2): 109-111.
[12]	JI Jia-lin, LIU Jing, WANG Xue-li, FENG Hong-lin, HAN Xu. Ameta-analysis and sequential analysis of the effects of Guanxinping on coronary heart disease [J]. Practical Geriatrics, 2023, 37(2): 128-133.
[13]	WEI Mei, GUO Qi-feng, DUAN Li-nan, YIN Ya-juan, LIU Gang, ZHENG Ming-qi, LIU Yong-sheng. Association between subclinical hypothyroidism and death in elderly patients after percutaneous coronary intervention [J]. Practical Geriatrics, 2023, 37(2): 138-141.
[14]	YAO Jun-xiu, GUO Jin-chun, HAO Xiao-dan, LI Long-xin, YANG Xue, WANG Zhang. Expression and diagnostic value of hepatocyte growth factor in patients with chronic coronary syndrome [J]. Practical Geriatrics, 2023, 37(2): 173-177.
[15]	. [J]. Practical Geriatrics, 2023, 37(2): 191-194.